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Abstract 
Context: Trigeminal neuralgia is as a chronic, debilitating condition, which can have a major impact on quality of 
life. There are few reports of trigeminal neuralgia in oriental populations. 
Objectives: To evaluate the retrospective data of the patients diagnosed with idiopathic trigeminal neuralgia and to 
understanding the disorder in the Indian populace. 
Methods: The retrospective data of 72 patients with typical idiopathic trigeminal neuralgia regarding age of onset, 
gender, site of involvement, clinical presentations and treatment received during three years of the follow up was 
collected and analyzed. 
Results: In the present retrospective study, the mean age was 54.9 years; female to male ratio was 2.13:1; rural to 
urban ratio 1.76:1 with 62.5% suffered trigeminal neuralgic pain on the right side. Carbamazepine was found to be 
highly effective in 60.8% of the cases on long-term basis with maintenance doses. Other treatment modalities were 
employed in more refractory cases including add-on of gabapentin, which relieved the symptoms for an additional 
duration of 13±3months. The neurolytic alcohol bloc was given in 30% of patients who stopped responding to com-
bination of carbamazepine and gabapentin and relieved pain for a mean duration of 17.25±2.95 months. Twenty 
three percent of the patients (23%) required peripheral neurectomy. 
Conclusions: Carbamazepine was found to be highly effective in trigeminal neuralgia. Other treatment modality 
includes add-on of gabapentin, neurolytic alcohol blocs and peripheral surgical intervention in more refractory 
cases. Only limited cases needed further neurological consideration.
Key words: Trigeminal neuralgia, carbamazepine, gabapentin, alcohol bloc, peripheral neurectomy.
doi:10.4317/jced.51771
http://dx.doi.org/10.4317/jced.51771
Article Number: 51771                http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System
Yadav S, Mittal HC, Sachdeva A, Verma A, Dhupar V, Dhupar A. A retro-
spective study of 72 cases diagnosed with idiopathic trigeminal neuralgia 
in indian populace. J Clin Exp Dent. 2015;7(1):e40-4.
http://www.medicinaoral.com/odo/volumenes/v7i1/jcedv7i1p40.pdf
J Clin Exp Dent. 2015;7(1):e40-4.                                                                                                                                                Retrospective study of patients with trigeminal neuralgia
e41
Introduction
Trigeminal neuralgia is as a chronic, debilitating con-
dition resulting in brief and intense episodes of facial 
pain in the distribution of one or more branches of the 
fifth cranial nerve (1-3). The episodes of facial pain are 
sporadic, sudden and often like “electric shocks”, lasting 
from a few seconds to several minutes. Etiology may 
be either idiopathic or secondary to intracranial lesions 
such as tumor, infarction and multiple sclerosis. Most of 
the cases are of idiopathic type with no underlying cause. 
Intracranial lesions that cause compression or traction 
of the trigeminal nerve are uncommon, but are a recog-
nized cause of secondary trigeminal neuralgia. Patients 
with multiple sclerosis may develop trigeminal neural-
gia; however, it is relatively rare. Trigeminal neuralgia is 
sometimes misdiagnosed due to non-availability of clear 
physical or laboratory diagnosis; and many a times, pa-
tient seek the help of numerous clinicians before a firm 
diagnosis is made. Though a benign disorder, it can have 
a major impact on quality of life and even gets refractory 
to various treatment modalities after some time.
Trigeminal neuralgia is rare and statistical data regar-
ding it is limited. The estimated annual incidence of tri-
geminal neuralgia is 12.6 per 100000 persons per year 
(4) and its incidence increases with age. Although peak 
onset occurs between age 50 and 70 years, the disorder 
can also occur in children. Early literature suggested a 
strong preponderance in women; however, current data 
indicate that only approximately 60% of patients with 
trigeminal neuralgia are female (5). The annual inciden-
ce for women is approximately 5.9 cases per 100,000 
women; for men, it is approximately 3.4 cases per 
100,000 men (6).
Unfortunately, there is no definitive cure for trigeminal 
neuralgia at present. Relapses and reoccurrences may 
occur with significant morbidity; however, plethora of 
medical and surgical treatment options do exist to alle-
viate the patient’s symptoms.
There are few reports of trigeminal neuralgia in orien-
tal populations (2,4,7). Because of the paucity of Indian 
data on incidence and management, a retrospective study 
of patients was undertaken with the purpose of unders-
tanding the disorder in the local context, and to compare 
with published data. 
Material and Methods 
The present retrospective study relates to a consecutive 
series of 72 patients with typical idiopathic trigeminal 
neuralgia reported in the Department of Maxillofa-
cial Surgery at the PDM Dental College Bahadurgarh, 
Haryana, India. Data for the study was retrieved from 
clinical patient records of patients reported during No-
vember 2009 to November 2010 and having been fo-
llowed regularly for a minimum of three years. Only 
those records that had attached informed consent for the 
treatment and teaching/research purpose were included 
for retrieval of data. The inclusion criteria were based on 
mentioned clinical and radiological diagnosis of typical 
idiopathic trigeminal neuralgia; and a positive diagnos-
tic local anesthetic test in the patient record sheet. The 
data regarding age of onset, gender, site of involvement, 
clinical presentations and treatment received during the 
follow up period was collected and analyzed. 
Results
The patient diagnosed with typical idiopathic trigemi-
nal neuralgia in the present retrospective study ranged 
between 34 to 76 years, with a mean age of 54.9 years. 
The peak incidence was in the fifth and sixth decades of 
life (Table 1). Females comprised 68 percent of the pa-
tients, representing a ratio of 2.13:1 (Table 2). Majority 
of the patients belonged to the rural patients with a ratio 
of 1.76:1 as compared with urban population. 
Age No. of patients Percentage (%)
3rd decade 3 4.16%
4th decade 12 16.66%
5th decade 24 33.33%
6th decade 22 30.55%
7th decade 11 12.27%
Table 1. Age at onset of trigeminal neuralgia.
Gender Urban Rural Total
Males 8 15 23 (31.94%)
Females 18 31 49 (68.05%)
Total 26 (36.11%) 46 (63.8%) 72
Table 2. Distribution according to gender and community.
Of the 72 cases, 45 patients (62.5%) suffered excrucia-
ting pain on the right side of the face and 27 patients 
on the left side (Table 3). This gave a site ratio of 1.6:1 
confirming a predominance of right side facial affliction. 
The mandibular division was the most frequently invol-
ved branch (Table 3). Forty-one patients (56.9 percent) 
reported neuralgic pain confined solely to the mandibular 
distribution of the face. Out of these reported mandibu-
lar division involvement cases, twenty-eight patients re-
ported inferior alveolar nerve involvements while other 
thirteen-reported neuralgic pain only in the distribution 
of mental nerve. Twenty-seven patients (37.5 percent) 
reported neuralgic pain in the distribution of maxillary 
nerve, all with infra orbital nerve involvement. Four 
patients (5.6 percent) suffered from this condition with 
the involvement of the maxillary and mandibular divi-
sion on the same side having involvement of mental and 
infra-orbital nerve involvement.
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NERVE Involved Right side Left Side Bilateral TOTAL
Maxillary nerve (V2) 16 11 -- 27
Mandibular nerve (V3) 26 15 -- 41
Maxillary and Mandibular (V2, V3) 03 01 -- 04
Opthalmic and Maxillary (V1,V2) -- -- -- --
Opthalmic(V1) -- -- -- --
All three Branches (V1, V2, V3) -- -- -- --
Table 3. Distribution of side of face and division of nerve involved.
Treatment in 69 (95.8 percent) of the 72 patients (Ta-
ble 4) was started with carbamazepine and responded 
well symptomatically initially, and remaining 3 (4.2 
percent) were directly treated with peripheral neurec-
tomy because these cases were known to be refractory 
to other treatment modalities and were referred from 
other centers for surgical management. Over a period of 
four to six months, 27 (39 percent) of the patients given 
carbamazepine required supplementary medication i.e. 
gabapentin. After a mean period of 13.38±3.73 months, 
Treated with Males Females Total patients
Carbamazepine 21 48 69
Carbamazepine and Gabapentin 10 17 27
Alcohol block in the vicinity of the nerve 8 13 21
Directly peripheral neurectomy 2 1 3
Peripheral neurectomy after receiving medicinal treatment 6 10 16
Carbamazepine after surgery 2 3 5
Referred to Neurologist 1 3 4
Table 4. Treatment received by the patients with idiopathic trigeminal neuralgia.
30% of the patients receiving medicinal treatment beca-
me refractory and treated with absolute alcohol injec-
tion (0.5 to 0.8 ml) for the particular affected peripheral 
branch (Table 4). Surgical modality (peripheral neurec-
tomy) was employed to further ease the pain (23%) in 16 
cases after a mean duration of 17.25±2.95 months. Out 
of 16 neurectomies, seven cases were operated for infra 
orbital, three cases for mental nerve and six cases for 
inferior alveolar nerve neurectomy respectively. Howe-
ver, 31% (n=5) of the patients underwent neurectomy 
required additional medicinal treatment after peripheral 
neurectomy in order to relieve symptoms. Out of these 
25% (n=4) cases were referred to neurologists for further 
evaluation and management when developed symptoms 
within 6 months of surgical therapy.
Discussion
Trigeminal neuralgia is an uncommon disorder seen in 
dental and neurologic practice, which presents with brief 
lancinating pain in the facial region in the area distribu-
ted by the trigeminal nerve. The disease is also known 
by less familiar names such as ‘Fotergill’s disease’ or 
‘tic douloureux’. Trigeminal neuralgia can be classified 
based on etiology as primary or idiopathic and secon-
dary or symptomatic.
The reported peak age of onset of trigeminal neuralgia 
is in fifth to eighth decades of life (6-8). Younger age 
has been found to be associated with symptomatic trige-
minal neuralgia. However, considerable overlap in age 
ranges of patient with classical trigeminal neuralgia and 
symptomatic trigeminal neuralgia has also been reported 
(9,10). Similar trend was also observed in the present 
study with the peak age of onset between fifth and sixth 
decades of life. 
In literature, female predominance has been reported in the 
ratio of 5.9:3.4 (6,8). Conversely, a male predominance has 
been reported in three reports from India (7). Although the 
disorder appeared to have a gender inclination, Zakrzewska 
(11) noted an equal representation of male to female inci-
dence when adjustment was made to account for the older 
female population. However, the present study favors the 
trait of female dominance, with a ratio of 2.13:1 reflecting 
an elevated risk for female subjects.
In the present study, a rural predominance in the ratio of 
1.76:1 compared to urban population was also observed. 
The one of possible reasons could be rural location of 
institute and thus easy accessibility to rural population. 
The other possibility could be hypothesized that rural 
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females are more prone to domestic violence, poor nu-
trition ignored behavior and with time the accumulated 
psychological stress may have some role in etiology or 
precipitation of trigeminal neuralgia.
Most commonly it is unilateral, but 3% of cases with 
bilateral involvement have also been reported. Bilateral 
cases need special attention due to complexity of presen-
tation and management (6,7,12). The trigeminal neural-
gia usually affects right side of face as reported in litera-
ture (8,13,14) and, present study also justifies the same 
observation as right side of the face was affected in the 
ratio 1.6:1. Not even a single case of bilateral trigeminal 
neuralgia was found in the present study.
In the present series about two third (62.5%) of the pa-
tients found to be affected with involvement of mandi-
bular division either alone or in combination with the 
maxillary division. The findings suggested mandibular 
division as most frequently affected branch of the fif-
th cranial nerve. The majority of published literature 
revealed that the mandibular division (V3) was most 
commonly involved and the ophthalmic division (V1) 
was less commonly presented (8,14-16). Shankland (15) 
reported that a third of the patients in their study presen-
ted with neuralgic pain involving both the second and 
third divisions of the fifth nerve. Approximately 6% of 
the patients in the present study also had involvement of 
both mandibular and maxillary divisions. 
The possible reason could be related to the inherent hig-
her prevalence with involvement of mandibular division 
in Asian population (8). The other possibility could be 
hospital bias yielded due to patients reporting to ophthal-
mologist for pain in the 1st division of 5th cranial nerve 
and does not report to maxillofacial or dental departments. 
Similarly, the patients with involvement of mandibular 
branch consults dental surgeon and those reporting to 
other specialty may be referred back to dental departments 
as the pain due to dental origin to be ruled out. 
Treatment of trigeminal neuralgia ranges from simple 
medical to complex surgical management. The first line 
of defense is medicinal which includes carbamazepi-
ne and other related anticonvulsant drugs. These drugs 
work as Na+ channel blockers and relieve pain in tri-
geminal neuralgia by suppressing membrane resonance 
and firing in injured afferents.
Carbamazepine is the most studied and remains the drug 
of choice for treating trigeminal neuralgia (2,8,9,17-20). 
Treatment begins with 100 to 200 mg two to three ti-
mes daily. Doses should be increased very progressively 
and titrated to the severity of the patient’s pain. In some 
cases a maintenance dosage of 200 to 400 mg per day 
is sufficient to keep the patient pain free. Studies have 
shown that it is effective in long-term treatment in 75% 
of the patients in whom the drug was initially effective 
(17). The controlled clinical trials showed to reduce pain 
severity, number of spontaneous paroxysms, and num-
ber of trigger (18). The present study also showed its 
effectiveness in 60.8% of the cases on long-term basis 
with maintenance doses.
In cases, where paroxysms of pain persist with therapeutic 
blood levels of carbamazepine, the second-line approach 
is add on therapy with baclofen, gabapentin, pregablin 
(8), lamotrigine, clonazepam, sodium valproate, phen-
ytoin sodium, opiates (21). However, formal conclusive 
studies are still lacking for these combination therapies. 
In present study, combination of carbamazepine and ga-
bapentin was given to 39% (n=27) patients who failed 
to respond with carbamazepine alone. Twenty-one pa-
tients (30%) stopped responding to combination of car-
bamazepine and gabapentin after an additional duration 
of 13±3months. Solaro et al. (22) in cases of trigeminal 
neuralgia with multiple sclerosis observed similar fin-
dings where co-administered carbamazepine and gaba-
pentin found to deliver synergistic effect on trigeminal 
neuralgia. Prisco et al. (23) also evaluated combination 
therapy (carbamazepine + gabapentin or carbamazepine 
+ pregabalin) in three patients refractory to antiepileptic 
medications and observed significant improvement du-
ring one year of follow up. Cheshire (24) also conclu-
ded in their retrospective study that gabapentin could be 
effective as first or second line treatment of trigeminal 
neuralgia, even in cases resistant to traditional treatment 
modalities. In their study, pain relief was obtained in 
43 patients and sustained in two thirds during a mean 
follow-up time of 8 months (24). Therefore, it could be 
hypothesized that the co-administration of carbamazepi-
ne and gabapentin has a synergistic effect on trigeminal 
neuralgic pain. 
The patients who do not respond to medicinal treatment, 
some form of surgery should be proposed. It is estimated 
that up to 50% of the patient will sooner or later be in 
this situation (17). The first surgical group falls under the 
peripheral procedures, which include neurolytic alcohol 
block, neurectomy, radiofrequency thermocoagulation 
of the peripheral branches, cryotherapy and peripheral 
acupuncture. The studies on the peripheral procedures 
showed that 50% of the patients had a recurrence of pain 
after one year but the morbidity is low (19). The complex 
surgical procedure includes rhizotomy, radiofrequency 
thermocoagulation and decompression of ganglion or 
main nerve trunk. There are no randomized controlled 
trials to guide comparisons between the surgical options 
available.
Alcohol injections are useful in those who are refrac-
tory to drug therapy and in whom surgery is delayed or 
defer for any reason. In a retrospective study, the distal 
injection technique relieved pain for a mean time inter-
val of 14.13 ± 8.66 months. There was a fall in the du-
ration of effect with subsequent injections (25). Another 
retrospective study was conducted from 1994-1999 by 
McLeod et al. (26) and found that peripheral alcohol 
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injection lasted for a mean of 11 months. However, a 
failure rate of 10% has been reported (26). In the present 
study, alcohol injection relieved pain for a mean dura-
tion of 17.25±2.95 months. The combination of efficacy 
and reduced morbidity makes this procedure preferable 
for the treatment of trigeminal neuralgia. 
In cases, where medicinal and alcohol block is ineffec-
tive or refractory with involvement of only one branch, 
peripheral neurectomy is a safe surgical method.  The 
reported success rate of peripheral neurectomy in few 
controlled studies ranges from 26%-75% over different 
time intervals (2). In contrast to these studies, one study 
found recurrence in 78% of patients who had undergone 
neurectomy during a mean follow up of 7 years. One-
half of these patients had their first recurrence within a 
month (27). In the present study, 16 patients (23%) re-
quired peripheral neurectomy and most patients within a 
few days have a decrease in pain severity or no pain at 
all. The complication of concern is the sensory loss in 
the area. The patients who had underwent surgery; the 
majority of them have preferred to have surgery earlier, 
similar to reported studies by Zakrzewska et al. (28). 
However, five patients (31%) required additional me-
dicinal treatment to control the pain. Out of these five 
patients, four were referred to neurosurgeon with in six 
months of peripheral neurectomy. Patients who have 
successful surgeries often need secondary or tertiary 
surgeries on different trigeminal nerve branches due to 
migration of pain. 
Medical treatment of trigeminal neuralgia is usually the 
first option; and Carbamazepine was found to be highly 
effective and specific for this condition. Other treatment 
modalities were employed in more refractory cases in-
cluding add-on of gabapentin and neurolytic alcohol 
blocs. Simple surgical intervention was used to relieve 
the intractable pain of those few patients who did not 
respond to medical therapy. Only a few cases needed 
further neurological consideration.
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